DOCSLIB.ORG

Synthesis, Anti-Inflammatory, Analgesic, COX1/2-Inhibitory Activity, and Molecular Docking Studies of Hybrid Pyrazole Analogues

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Synthesis, Anti-Inflammatory, Analgesic, COX1/2-Inhibitory Activity, and Molecular Docking Studies of Hybrid Pyrazole Analogues Journal name: Drug Design, Development and Therapy Article Designation: Original Research Year: 2016 Volume: 10 Drug Design, Development and Therapy Dovepress Running head verso: Alam et al Running head recto: Hybrid pyrazole analogues open access to scientific and medical research DOI: http://dx.doi.org/10.2147/DDDT.S118297 Open Access Full Text Article ORIGINAL RESEARCH Synthesis, anti-inflammatory, analgesic, COX1/2-inhibitory activity, and molecular docking studies of hybrid pyrazole analogues Md Jahangir Alam1 Abstract: This article reports on the design, synthesis, and pharmacological activity of a new Ozair Alam1 series of hybrid pyrazole analogues: 5a–5u. Among the series 5a–5u, the compounds 5u and 5s Suroor Ahmad Khan1 exhibited potent anti-inflammatory activity of 80.63% and 78.09% and inhibition of 80.87% and Mohd Javed Naim1 76.56% compared with the standard drug ibuprofen, which showed 81.32% and 79.23% inhibi- Mohammad Islamuddin2 tion after 3 and 4 hours, respectively. On the basis of in vivo studies, 12 compounds were selected Girdhar Singh Deora3 for assessment of their in vitro inhibitory action against COX1/2 and TNFα. The compounds 5u and 5s showed high COX2-inhibitory activity, with half-maximal inhibitory concentrations 1 Department of Pharmaceutical of 1.79 and 2.51 µM and selectivity index values of 72.73 and 65.75, respectively, comparable Chemistry, Faculty of Pharmacy, 2Parasite Immunology Laboratory, to celecoxib (selectivity index =78.06). These selected compounds were also tested for TNFα, For personal use only. Department of Biotechnology, Faculty cytotoxicity, and ulcerogenicity. Docking studies were also carried out to determine possible of Science, Jamia Hamdard, New Delhi, interactions of the potent compounds (5u and 5s), which also showed high docking scores 3Institute of Life Sciences, University of Hyderabad, Hyderabad, India of -12.907 and -12.24 compared to celecoxib, with a -9.924 docking score. These selective COX2 inhibitors were docked into the active site of COX2, and showed the same orientation and binding mode to that of celecoxib (selective COX2 inhibitor). Docking studies also showed that the SO2NH2 of 5u and 5s is inserted deep inside the selective pocket of the COX2-active site and formed a hydrogen-bond interaction with His90, Arg513, Phe518, Ser353, Gln192, and Ile517, which was further validated by superimposed docked pose with celecoxib. Keywords: anti-inflammatory activity, analgesic activity, selective COX2 inhibition, TNFα inhibition, molecular docking studies, pyrazole Introduction Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used therapeutic Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 130.194.145.11 on 19-Jun-2017 agents for the management of pain and inflammation.1 NSAIDs exert their pharmacological action by inhibiting COX enzymes, which catalyses the conversion of arachidonic acid to prostaglandins, prostacyclins, and thromboxanes.2 Two differ- ent isoforms of COX exist (COX1 [constitutive] and COX2 [inducible]), which are assumed to play a vital role in producing pathological and physiological prostaglandins, respectively.3 Currently used NSAIDs employ their anti-inflammatory action mostly by inhibition of both isoforms of COX.4–6 However, absence of selectivity and their Correspondence: Ozair Alam Department of Pharmaceutical long-term clinical use leads to various adverse effects, such as gastric ulceration, Chemistry, Room No 209, Faculty of gastrointestinal bleeding, cardiovascular toxicity, and nephrotoxicity, which are mainly Pharmacy, Jamia Hamdard, Hamdard associated with most of the reported nonselective NSAIDs, due to their inhibition of Nagar, Near Batra Hospital, New Delhi, Delhi 110062, India COX1-mediated physiological prostaglandins.7–9 Similarly, NFκB also plays a key role Tel +91 11 2605 9681 by activating the inflammatory response and releasing proinflammatory cytokines and Fax +91 11 2605 9666 Email [email protected] enzymes, such as TNFα, IL-1β, COX2, and iNOS.10,11 Improper regulation of NFκB submit your manuscript | www.dovepress.com Drug Design, Development and Therapy 2016:10 3529–3543 3529 Dovepress © 2016 Alam et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you http://dx.doi.org/10.2147/DDDT.S118297 hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Powered by TCPDF (www.tcpdf.org) 1 / 1 Alam et al Dovepress is directly linked to inflammation, together with improper continuation of our previous work, the present investigation immunodevelopment.12–14 describes the synthesis, anti-inflammatory, and analgesic Pyrazole, a key heterocyclic scaffold in medicinal chem- activities of substituted pyrazole analogues with the aim istry, possess an array of various biological activities, such of obtaining nonulcerogenic selective COX2 inhibitors as as antitumor,15 anticancer,16,17 antiviral,18 anticonvulsant,19 anti-inflammatory agents. Moreover, in order to increase antibacterial,20 and antifungal21 activity. The rationale for affinity for COX2, the bulky hydrophobic benzyloxyphenyl evaluating pyrazole analogues (5a–5u) as anti-inflammatory, group was incorporated in a manner similar to orientation analgesic, and COX inhibitors is based on successful of the trifluoromethyl group of celecoxib. Further, the marketed drugs containing pyrazole as the central core importance of this bulky hydrophobic group was noticed by (celecoxib, SC558, deracoxib, SC560, metamizole, anti- formation of one hydrogen bond with Arg120 in molecular pyrine, SC581, and lonazolac) (Figure 1). The design of docking studies. The high in vitro COX2-inhibition assay NSAIDs with higher therapeutic value and lower risk could results of compounds 5u and 5s encouraged us to perform be achieved by increasing specificity toward COX2 rather molecular docking studies to establish and understand than COX1.22–24 In the present study, the central pyrazole the ligand–protein interactions. The in vitro COX assay core linked with the phenylsulfonamide group of selective and docking study results showed that the N1 substituent COX2 inhibitors (celecoxib and SC558) was employed, and of the core pyrazole structure with benzene sulfonamide structural modification led to the design of new pyrazole moiety is important for selective COX2-inhibitory activity. analogues (Figure 2). Docking studies also revealed that the SO2NH2 group of Further the pyrazole moiety was linked to two aryl moi- 5u and 5s, as well as celecoxib,27 formed hydrogen bonds eties, of which one was linked through the –CH2NH linker with His90, Arg513, Phe518, Ser353, Gln192, and Ile517, and the other through the –OCH2 linker. The significance and was completely inserted in the selective pocket of the of our study is in bringing together the pyrazole (excellent COX2-active site. anti-inflammatory agent) and sulfonamide pharmacophore, Encouraged by all these facts, we designed a new For personal use only. known too for its wide range of biological activities, includ- series of hybrid pyrazole analogues (5a–5u) bearing the ing anti-inflammatory activities,25,26 to obtain a derivative N-phenyly/p-sulfonamide phenyl group involving various that is new and with a better pharmacological profile with electron-withdrawing and electron-releasing substituents fewer side effects. As part of our continuous research and and in vivo anti-inflammatory, analgesic, ulcerogenic, efforts to design and develop a novel pyrazole-based anti- in vitro COX1/COX2 selective, TNFα, iNOS and cytotoxic inflammatory agent with COX1/2-inhibition effect and activity. ) ) ) %U ) ) ) 2 ) &, ) ) ) ) 11 11 ) ) 11 11 Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 130.194.145.11 on 19-Jun-2017 6 2 6 2 6 2 2 2 1+ 2 1+ 2 1+ &HOHFR[LE 6& 'HUDFR[LE 6& 2+ ) ) 2 2 ) 6 +2 2 2 ) &, 11 1 11 2 11 11 6 2 2 1+ 0HWDPL]ROH $QWLS\ULQH 6& /RQD]RODF Figure 1 Chemical structure of some pyrazole-containing anti-inflammatory drugs. 3530 submit your manuscript | www.dovepress.com Drug Design, Development and Therapy 2016:10 Dovepress Powered by TCPDF (www.tcpdf.org) 1 / 1 Dovepress Hybrid pyrazole analogues ) ) ) 1 6HU$ 3KH$ 1 %U ,OH$ *OQ$ $UJ$ 226 2 1+ 6HU$ +LV$ 6& /LQNHU $UJ$ 1 6XSHULPSRVHGRFNHGSRVHRIFHOHFR[LE 1 ) ) SLQN ZLWKFRPSRXQGX JUHHQ ) $UELWUDU\UHJLRQ 1 1 226 0ROHFXODUGRFNLQJRQ&2; 1+ 0HW 226 +\GRSKRELF 9DO 1+ SRFNHW /HX ,& 0 &HOHFR[LE DJDLQVW&2; $UJ +LV /HX ,QYLYRDQWLLQIODPPDWRU\DFWLYLW\ 0HW 2 7\U /HX ,QYLWUR&2;DVVD\ ,OH *O\ /HX 1 6HU $OD + 6HU 71)αDVVD\ 1 9DO 9DO 1 *O\ /HX L126LQKLELWRU\DFWLYLW\ $OD +\GRSKRELF 0HW SRFNHW *OQ 3KH 3KH For personal use only. 2 $QDOJHVLFDFWLYLW\ 6 2 ,OH +1 &\WRWR[LFLW\DQGXOFHURJHQLFLW\ 6HOHFWLYLW\ /HX SRFNHW 7\U 7US 'HVLJQHGFRPSRXQG Figure 2 Strategy for design of target compound with structural resemblance of reference ligand. Abbreviation: IC50, half-maximal inhibitory concentration. (DMSO)-d or CDCl as an NMR solvent. Ultraperformance Materials and methods 6 3 General chemistry liquid chromatography (UPLC) analysis
Load more

Recommended publications
  • Table S1: Sensitivity, Specificity, PPV, NPV, and F1 Score of NLP Vs. ICD for Identification of Symptoms for (A) Biome Developm
    Table S1: Sensitivity, specificity, PPV, NPV, and F1 score of NLP vs. ICD for identification of symptoms for (A) BioMe development cohort; (B) BioMe validation cohort; (C) MIMIC-III; (D) 1 year of notes from patients in BioMe calculated using manual chart review. A) Fatigue Nausea and/or vomiting Anxiety Depression NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.99 (0.93- 0.59 (0.43- <0.00 0.25 (0.12- <0.00 <0.00 0.54 (0.33- Sensitivity 0.99 (0.9 – 1) 0.98 (0.88 -1) 0.3 (0.15-0.5) 0.85 (0.65-96) 0.02 1) 0.73) 1 0.42) 1 1 0.73) 0.57 (0.29- 0.9 (0.68- Specificity 0.89 (0.4-1) 0.75 (0.19-1) 0.68 0.97 (0.77-1) 0.03 0.98 (0.83-1) 0.22 0.81 (0.53-0.9) 0.96 (0.79-1) 0.06 0.82) 0.99) 0.99 (0.92- 0.86 (0.71- 0.94 (0.79- 0.79 (0.59- PPV 0.96 (0.82-1) 0.3 0.95 (0.66-1) 0.02 0.95 (0.66-1) 0.16 0.93 (0.68-1) 0.12 1) 0.95) 0.99) 0.92) 0.13 (0.03- <0.00 0.49 (0.33- <0.00 0.66 (0.48- NPV 0.89 (0.4-1) 0.007 0.94 (0.63-1) 0.34 (0.2-0.51) 0.97 (0.81-1) 0.86 (0.6-0.95) 0.04 0.35) 1 0.65) 1 0.81) <0.00 <0.00 <0.00 F1 Score 0.99 0.83 0.88 0.57 0.95 0.63 0.82 0.79 0.002 1 1 1 Itching Cramp Pain NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.98 (0.86- 0.24 (0.09- <0.00 0.09 (0.01- <0.00 0.52 (0.37- <0.00 Sensitivity 0.98 (0.85-1) 0.99 (0.93-1) 1) 0.45) 1 0.29) 1 0.66) 1 0.89 (0.72- 0.5 (0.37- Specificity 0.96 (0.8-1) 0.98 (0.86-1) 0.68 0.98 (0.88-1) 0.18 0.5 (0-1) 1 0.98) 0.66) 0.88 (0.69- PPV 0.96 (0.8-1) 0.8 (0.54-1) 0.32 0.8 (0.16-1) 0.22 0.99 (0.93-1) 0.98 (0.87-1) NA* 0.97) 0.98 (0.85- 0.57 (0.41- <0.00 0.58 (0.43- <0.00 NPV 0.98 (0.86-1) 0.5 (0-1) 0.02 (0-0.08) NA* 1) 0.72) 1 0.72) 1 <0.00 <0.00 <0.00 F1 Score 0.97 0.56 0.91 0.28 0.99 0.68 1 1 1 *Denotes 95% confidence intervals and P values that could not be calculated due to insufficient cells in 2x2 tables.
    [Show full text]
  • Properties, Synthesis and Transformations Pedro M
    molecules Review ReviewStyrylpyrazoles: Properties, Synthesis and Styrylpyrazoles:Transformations Properties, Synthesis and Transformations Pedro M. O. Gomes, Pedro M. S. Ouro, Artur M. S. Silva * and Vera L. M. Silva * PedroLAQV-REQUIMTE, M. O. Gomes Department, Pedro M.of Chemistry, S. Ouro, Artur University M. S. of Silva Aveiro, * 3810-193and Vera Aveiro, L. M. Portugal; Silva * LAQV-REQUIMTE,[email protected] (P.M.O.G.); Department [email protected] of Chemistry, University(P.M.S.O.) of Aveiro, 3810-193 Aveiro, Portugal; [email protected]* Correspondence: (P.M.O.G.); [email protected] [email protected] (A.M.S.S.); (P.M.S.O.) [email protected] (V.L.M.S.); Tel.: +351-234-370714 (A.M.S.S.); * Correspondence:+351-234-370704 (V.L.M.S.) [email protected] (A.M.S.S.); [email protected] (V.L.M.S.); Tel.: +351-234-370714 (A.M.S.S.); +351-234-370704 (V.L.M.S.) Academic Editor: Derek J. McPhee Academic Editor: Derek J. McPhee Received: 21 November 2020; Accepted: 9 December 2020; Published: date Received: 21 November 2020; Accepted: 9 December 2020; Published: 12 December 2020 Abstract: The pyrazole nucleus and its reduced forms, pyrazolines and pyrazolidine, are privileged Abstract:scaffolds inThe medicinal pyrazole chemistry nucleus and due its to reduced their rema forms,rkable pyrazolines biological and activities. pyrazolidine, A huge are number privileged of scapyrazoleffolds inderivatives medicinal have chemistry been duestudied to their and remarkablereported over biological time. activities.This review A hugearticle number gives an of pyrazoleoverview derivatives of pyrazole have derivatives been studied that and contain reported a styryl over time.
    [Show full text]
  • POISONS LIST APPENDIX Amoebicides: Carbarsone
    POISONS LIST APPENDIX Amoebicides: Carbarsone Clioquinol and other halogenated hydroxyquinoline compounds Dehydroemetine; its salts Diloxanide; its compounds Dimetridazole Emetine Ipronidazole Metronidazole Pentamidine; its salts Ronidazole Anaesthetics: Alphadolone acetate Alphaxolone Desflurane Disoprofol Enflurane Ethyl ether Etomidate; its salts Halothane Isoflurane Ketamine; its salts Local anaesthetics, the following: their salts; their homologues and analogues; their molecular compounds Amino-alcohols esterified with benzoic acid, phenylacetic acid, phenylpropionic acid, cinnamic acid or the derivatives of these acids; their salts Benzocaine Bupivacaine Butyl aminobenzoate Cinchocaine Diperodon Etidocaine Levobupivacaine Lignocaine Mepivacaine Orthocaine Oxethazaine Phenacaine Phenodianisyl Prilocaine Ropivacaine Phencyclidine; its salts Propanidid Sevoflurane Tiletamine; its salts Tribromoethanol Analeptics and Central Stimulants: Amiphenazole; its salts Amphetamine (DD) Bemegride Cathine Cathinone (DD) Dimethoxybromoamphetamine (DOB) (DD) 2, 5-Dimethoxyamphetamine (DMA) (DD) 2, 5-Dimethoxy-4-ethylamphetamine (DOET) (DD) Ethamivan N-Ethylamphetamine; its salts N-Ethyl MDA (DD) N-Hydroxy MDA (DD) Etryptamine (DD) Fencamfamine Fenetylline Lefetamine or SPA or (-)-1-dimethylamino-1, 2-diphenylethane Leptazol Lobelia, alkaloids of Meclofenoxate; its salts Methamphetamine (DD) Methcathinone (DD) 5-Methoxy-3, 4-methylenedioxyamphetamine (MMDA) (DD) Methylenedioxyamphetamine (MDA) (DD) 3, 4-Methylenedioxymetamphetamine (MDMA) (DD) Methylphenidate;
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl Et Al
    US 2005O249806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl et al. (43) Pub. Date: Nov. 10, 2005 (54) COMBINATION OF PROTON PUMP Related U.S. Application Data INHIBITOR, BUFFERING AGENT, AND NONSTEROIDAL ANTI-NFLAMMATORY (60) Provisional application No. 60/543,636, filed on Feb. DRUG 10, 2004. (75) Inventors: Gerald T. Proehl, San Diego, CA (US); Publication Classification Kay Olmstead, San Diego, CA (US); Warren Hall, Del Mar, CA (US) (51) Int. Cl." ....................... A61K 9/48; A61K 31/4439; A61K 9/20 Correspondence Address: (52) U.S. Cl. ............................................ 424/464; 514/338 WILSON SONS IN GOODRICH & ROSAT (57) ABSTRACT 650 PAGE MILL ROAD Pharmaceutical compositions comprising a proton pump PALO ALTO, CA 94304-1050 (US) inhibitor, one or more buffering agent and a nonsteroidal ASSignee: Santarus, Inc. anti-inflammatory drug are described. Methods are (73) described for treating gastric acid related disorders and Appl. No.: 11/051,260 treating inflammatory disorders, using pharmaceutical com (21) positions comprising a proton pump inhibitor, a buffering (22) Filed: Feb. 4, 2005 agent, and a nonsteroidal anti-inflammatory drug. US 2005/0249806 A1 Nov. 10, 2005 COMBINATION OF PROTON PUMP INHIBITOR, of the Stomach by raising the Stomach pH. See, e.g., U.S. BUFFERING AGENT, AND NONSTEROIDAL Pat. Nos. 5,840,737; 6,489,346; and 6,645,998. ANTI-NFLAMMATORY DRUG 0007 Proton pump inhibitors are typically prescribed for Short-term treatment of active duodenal ulcers, gastrointes CROSS REFERENCE TO RELATED tinal ulcers, gastroesophageal reflux disease (GERD), Severe APPLICATIONS erosive esophagitis, poorly responsive Symptomatic GERD, 0001.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of - Medicines belonging to the ATC group M01 (Antiinflammatory and antirheumatic products) Table of Contents Page INTRODUCTION 6 DISCLAIMER 8 GLOSSARY OF TERMS USED IN THIS DOCUMENT 9 ACTIVE SUBSTANCES Phenylbutazone (ATC: M01AA01) 11 Mofebutazone (ATC: M01AA02) 17 Oxyphenbutazone (ATC: M01AA03) 18 Clofezone (ATC: M01AA05) 19 Kebuzone (ATC: M01AA06) 20 Indometacin (ATC: M01AB01) 21 Sulindac (ATC: M01AB02) 25 Tolmetin (ATC: M01AB03) 30 Zomepirac (ATC: M01AB04) 33 Diclofenac (ATC: M01AB05) 34 Alclofenac (ATC: M01AB06) 39 Bumadizone (ATC: M01AB07) 40 Etodolac (ATC: M01AB08) 41 Lonazolac (ATC: M01AB09) 45 Fentiazac (ATC: M01AB10) 46 Acemetacin (ATC: M01AB11) 48 Difenpiramide (ATC: M01AB12) 53 Oxametacin (ATC: M01AB13) 54 Proglumetacin (ATC: M01AB14) 55 Ketorolac (ATC: M01AB15) 57 Aceclofenac (ATC: M01AB16) 63 Bufexamac (ATC: M01AB17) 67 2 Indometacin, Combinations (ATC: M01AB51) 68 Diclofenac, Combinations (ATC: M01AB55) 69 Piroxicam (ATC: M01AC01) 73 Tenoxicam (ATC: M01AC02) 77 Droxicam (ATC: M01AC04) 82 Lornoxicam (ATC: M01AC05) 83 Meloxicam (ATC: M01AC06) 87 Meloxicam, Combinations (ATC: M01AC56) 91 Ibuprofen (ATC: M01AE01) 92 Naproxen (ATC: M01AE02) 98 Ketoprofen (ATC: M01AE03) 104 Fenoprofen (ATC: M01AE04) 109 Fenbufen (ATC: M01AE05) 112 Benoxaprofen (ATC: M01AE06) 113 Suprofen (ATC: M01AE07) 114 Pirprofen (ATC: M01AE08) 115 Flurbiprofen (ATC: M01AE09) 116 Indoprofen (ATC: M01AE10) 120 Tiaprofenic Acid (ATC:
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,309,630 B1 Patel Et Al
    USOO630963OB1 (12) United States Patent (10) Patent No.: US 6,309,630 B1 Patel et al. (45) Date of Patent: Oct. 30, 2001 (54) NON-STEROIDAL ANTI-INFLAMMATORY 5,296,228 3/1994 Chang et al. ........................ 424/422 OPHTHALMC SUSPENSIONS 5,340,572 8/1994 Patel et al. ........................... 514/913 (75) Inventors: Rajesh Patel, San Mateo; Lyle M. FOREIGN PATENT DOCUMENTS Bowman, Pleasanton; Peng Shen, 2839752 * 10/1979 (DE). Hayward, all of CA (US) 58-174310 1/1984 (JP). 58-174309 1/1994 (JP). (73) Assignee: Insite Vision Incorporated, Alameda, WO 94/10976 5/1994 (WO). CA (US) OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this Weisweiler, P.S. et al., Comparative Comfort of Flurbiprofen patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. Solution and Indomethacin Suspension Eyedrops, J. Clinical Res. & Drug Dev. 2: 233-239 (Dec. 1988). Vulovic, N. et al. Some Studies into the Properties of (21) Appl. No.: 08/248,500 Indomethacin Suspensions Intended for Ophthalmic Use, (22) Filed: May 24, 1994 Intl. J. of Pharmaceutics 55: 123-128 (Apr. 1989). (51) Int. Cl." ........................................................ S61K 9/10 * cited by examiner (52) U.S. Cl. ........................................................... 424/78.04 (58) Field of Search .......................... 514/913; 424/78.04 Primary Examiner-Peter F. Kulkosky (74) Attorney, Agent, or Firm Arnold & Porter (56) References Cited (57) ABSTRACT U.S. PATENT DOCUMENTS Compositions for topical ophthalmic application comprising 4,559,343 12/1985 Han et al. ............................ 514/264 an aqueous mixture of a non-Steroidal anti-inflammatory 4,829,083 5/1989 Doulakas .....
    [Show full text]
  • A Methocarbamol Combination to Prevent Toxicity of Non-Steroidal Anti Inflammatory Drugs
    88ORIGINAL Seung-Min ARTICLE Yeom, et al. Various Ways to Prevent Toxicity of Non-steroidal Anti Inflammatory Drugs Korean J Clin Lab Sci. 2017;49(2):88-98 https://doi.org/10.15324/kjcls.2017.49.2.88 pISSN 1738-3544 eISSN 2288-1662 A Methocarbamol Combination to Prevent Toxicity of Non-steroidal Anti Inflammatory Drugs Seung-Min Yeom1,2, Min-Seok Kim1,3, Eric Lingenfelter1,4, Jonathan Broadwell5 1USFK, Army 2nd Infantry Division, Camp Hovey Combined Troops Medical Aid Station, Dongducheon, Korea 2College of Pharmacy, Woo-suk University, Jeonju, Korea 3College of Nursing, Chung-Ang University, Seoul, Korea 4Defense Health Agency, Washington, USA 5Army National Guard, University of Utah School of Medicine, Salt Lake, USA 비스테로이드성 항염증제의 약물독성 예방을 위한 Methocarbamol의 약물조합 염승민1,2, 김민석1,3, Eric Lingenfelter1,4, Jonathan Broadwell5 1주한미군 육군 제2보병사단 캠프호비 클리닉, 2우석대학교 약학대학, 3중앙대학교 간호대학, 4미국 국방보건국, 5미국 주방위군, 유타대학교 의과대학 To prevent toxicity from both robax platinum (methocarbamol, ibuprofen) and robaxacet (methocarbomol, acetaminophen), separately, we used stretches and naproxen as a non-steroidal anti-inflammatory drug (NSAID) to compare each effectiveness. This study used the United States Forces Korea Prescription form (Annex A-Over-The-Counter Prescription) and Alice Rich’s Pain scale with robax platinum, robaxacet including narproxen. The IBM SPSS statics version 24 was used to calculate the data. The combined methocarbamol 500 mg, acetaminophen 325 mg tablet, and ibuprofen 200 mg (or naproxen) tablet can work as well as the combined methocarbamol 500 mg tablet with acetaminophen 325 mg tablet with stretches. Both methods were successful in managing pain. The drug combination of methocarbamol 500 mg, acetaminophen 325 mg and Corresponding author: Seung-Min Yeom ibuprofen 200 mg tablets yielded similar benefits as the methocarbamol 500 mg and USFK, Army 2nd Infantry Division, Camp Hovey acetaminophen 325 mg tablets paired with physical stretching exercises regarding managing Combined Troops Medical Aid Station, 2557 Pyeonghwa-ro, Dongducheon 11311, Korea overall pain.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Plants As Sources of Anti-Inflammatory Agents
    molecules Review Plants as Sources of Anti-Inflammatory Agents Clara dos Reis Nunes 1 , Mariana Barreto Arantes 1, Silvia Menezes de Faria Pereira 1, Larissa Leandro da Cruz 1, Michel de Souza Passos 2, Luana Pereira de Moraes 1, Ivo José Curcino Vieira 2 and Daniela Barros de Oliveira 1,* 1 Laboratório de Tecnologia de Alimentos, Centro de Ciências e Tecnologias Agropecuárias, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, RJ 28013-602, Brazil; [email protected] (C.d.R.N.); [email protected] (M.B.A.); [email protected] (S.M.d.F.P.); [email protected] (L.L.d.C.); [email protected] (L.P.d.M.) 2 Laboratório de Ciências Químicas, Centro de Ciências e Tecnologia, UniversidadeEstadual do Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, RJ 28013-602, Brazil; [email protected] (M.d.S.P.); [email protected] (I.J.C.V.) * Correspondence: [email protected]; Tel.: +55-22-988395160 Academic Editors: Thea Magrone, Rodrigo Valenzuela and Karel Šmejkal Received: 29 June 2020; Accepted: 5 August 2020; Published: 15 August 2020 Abstract: Plants represent the main source of molecules for the development of new drugs, which intensifies the interest of transnational industries in searching for substances obtained from plant sources, especially since the vast majority of species have not yet been studied chemically or biologically, particularly concerning anti-inflammatory action. Anti-inflammatory drugs can interfere in the pathophysiological process of inflammation, to minimize tissue damage and provide greater comfort to the patient. Therefore, it is important to note that due to the existence of a large number of species available for research, the successful development of new naturally occurring anti-inflammatory drugs depends mainly on a multidisciplinary effort to find new molecules.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]